The news: A new clinical study shows Roche’s obesity drug candidate resulted in up to 22.5% weight loss, rivaling results from GLP-1 market leaders Novo Nordisk and Eli Lilly.
- Roche’s mid-stage results for the weekly injection resulted in 22.5% average weight loss for patients who adhered to the treatment plan after 48 weeks.
- Weight loss rates were 18.3% for all patients on the drug regardless of adherence.
Why it matters: Novo and Lilly are splitting command of the GLP-1 weight loss drug market now, but several Big Pharmas like Roche, Amgen, and Pfizer are advancing their drug candidates, aiming to join the growing and lucrative market.
Implications for pharma marketers and consumers: As more obesity drugs enter the market, patients and doctors gain more options, while brands struggle to stand out among competitors with similar costs and results..
For pharma marketers, competition will shift beyond pricing and weight loss numbers toward differentiation around target populations, adherence, and clinical positioning. Competition from Big Pharmas like Roche and Pfizer will raise the pressure, pushing brands to rethink messaging, patient support, provider education, and payer relationships.
For consumers, growing competition could eventually improve access and affordability. However, in the shorter term, education and support programs—along with expansion into conditions like heart disease, liver disease, and sleep apnea—will play a bigger role in uptake as the market shifts to a more crowded field.
This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.